Subarachnoid hemorrhage: management considerations for COVID-19

Eric J. Panther , Brandon Lucke-Wold

Exploration of Neuroprotective Therapy ›› 2022, Vol. 2 ›› Issue (2) : 65 -73.

PDF (1534KB)
Exploration of Neuroprotective Therapy ›› 2022, Vol. 2 ›› Issue (2) :65 -73. DOI: 10.37349/ent.2022.00018
Review
research-article
Subarachnoid hemorrhage: management considerations for COVID-19
Author information +
History +
PDF (1534KB)

Abstract

Subarachnoid hemorrhage (SAH) has deleterious outcomes for patients, and during the hospital stay, patients are susceptible to vasospasm and delayed cerebral ischemia. Coronavirus disease 2019 (COVID-19) has been shown to worsen hypertension through angiotensin-converting enzyme 2 (ACE2) activity, therefore, predisposing to aneurysm rupture. The classic renin-angiotensin pathway activation also predisposes to vasospasm and subsequent delayed cerebral ischemia. Matrix metalloproteinase 9 upregulation can lead to an inflammatory surge, which worsens outcomes for patients. SAH patients with COVID-19 are more susceptible to ventilator-associated pneumonia, reversible cerebral vasoconstriction syndrome, and respiratory distress. Emerging treatments are warranted to target key components of the anti-inflammatory cascade. The aim of this review is to explore how the COVID-19 virus and the intensive care unit (ICU) treatment of severe COVID can contribute to SAH.

Keywords

Subarachnoid hemorrhage / COVID-19 / renin-angiotensin pathway / matrix metalloproteinase 9 / outcomes

Cite this article

Download citation ▾
Eric J. Panther, Brandon Lucke-Wold. Subarachnoid hemorrhage: management considerations for COVID-19. Exploration of Neuroprotective Therapy, 2022, 2 (2) : 65-73 DOI:10.37349/ent.2022.00018

登录浏览全文

4963

注册一个新账户 忘记密码

References

[1]

Batcik OE, Kanat A, Cankay TU, Ozturk G, Kazancioglu L, Kazdal H, et al. COVID-19 infection produces subarachnoid hemorrhage; acting now to understand its cause: a short communication. Clin Neurol Neurosurg. 2021; 202: 106495.

[2]

Kanat A. Letter to the editor regarding “aneurysmal subarachnoid hemorrhage in COVID-19 patients: a case series”. World Neurosurg. 2021; 154: 199.

[3]

Kanat A. Letter to the editor regarding “subarachnoid hemorrhage and COVID-19: an analysis of 282,718 patients”. World Neurosurg. 2021; 155: 200-1.

[4]

Chappell MC. Nonclassical renin-angiotensin system and renal function. Compr Physiol. 2012; 2: 2733-52.

[5]

Gök G. COVID-19’da kardiyovasküler sistem tutulumunun epidemiyolojisi. In: Duman D, editor. COVID-19 ve kardiyovasküler sistem. 1. Baskı. Ankara: Türkiye Klinikleri; 2021. pp. 1-3. Turkish.

[6]

Ozmen S, Altinkaynak K, Aydin MD, Ahiskalioglu A, Demirci T, Ödž zlü C, et al. Toward understanding the causes of blood pH irregularities and the roles of newly described binuclear neurons of carotid bodies on blood pH regulation during subarachnoid hemorrhage: experimental study. Neuropathology. 2019; 39: 259-67.

[7]

Alotaibi AS, Mahroos RA, Al Yateem SS, Menezes RG. Central nervous system causes of sudden unexpected death: a comprehensive review. Cureus. 2022; 14: e20944.

[8]

Macdonald RL. Delayed neurological deterioration after subarachnoid haemorrhage. Nat Rev Neurol. 2014; 10: 44-58.

[9]

Aydin MD, Kanat A, Yolas C, Soyalp C, Onen MR, Yilmaz I, et al. Spinal subarachnoid hemorrhage induced intractable miotic pupil. A reminder of ciliospinal sympathetic center ischemia based miosis: an experimental study. Turk Neurosurg. 2019; 29: 434-9.

[10]

Hutchinson PJ, Seeley HM, Kirkpatrick PJ. Factors implicated in deaths from subarachnoid haemorrhage: are they avoidable? Br J Neurosurg. 1998; 12: 37-40.

[11]

Li R, Lin F, Chen Y, Lu J, Han H, Yan D, et al. In-hospital complication-related risk factors for discharge and 90-day outcomes in patients with aneurysmal subarachnoid hemorrhage after surgical clipping and endovascular coiling: a propensity score-matched analysis. J Neurosurg. 2021;[Epub ahead of print].

[12]

Lozada-Martíƴnez ID, Rodríƴguez-Gutiérrez MM, Ospina-Rios J, Ortega-Sierra MG, González-Herazo MA, Ortiz-Roncallo LM, et al. Neurogenic pulmonary edema in subarachnoid hemorrhage: relevant clinical concepts. Egypt J Neurosurg. 2021; 36: 27.

[13]

Naredi S, Lambert G, Edén E, Zäll S, Runnerstam M, Rydenhag B, et al. Increased sympathetic nervous activity in patients with nontraumatic subarachnoid hemorrhage. Stroke. 2000; 31: 901-6.

[14]

Tang H, Wang Q, Xu F, Zhang X, Zeng Z, Yan Y, et al. Underlying mechanism of hemodynamics and intracranial aneurysm. Chin Neurosurg J. 2021; 7: 44.

[15]

Saqr KM, Tupin S, Rashad S, Endo T, Niizuma K, Tominaga T, et al. Physiologic blood flow is turbulent. Sci Rep. 2020; 10: 15492.

[16]

Akpek M. Does COVID-19 cause hypertension? Angiology. 2021;[Epub ahead of print].

[17]

Alwahdy AS, Margaretha IY, Pramesti KS, Hamro N, Yuzella V, Nasution F, et al. Case series of intravenous thrombolysis for acute ischemic stroke in confirmed COVID-19 patients: single-centre experience. Egypt J Neurol Psychiatr Neurosurg. 2022; 58: 5.

[18]

Dakay K, Kaur G, Gulko E, Santarelli J, Bowers C, Mayer SA, et al. Reversible cerebral vasoconstriction syndrome and dissection in the setting of COVID-19 infection. J Stroke Cerebrovasc Dis. 2020; 29: 105011.

[19]

Cañas CA, Cañas F, Bautista-Vargas M, Bonilla-Abadíƴa F. Role of tissue factor in the pathogenesis of COVID-19 and the possible ways to inhibit it. Clin Appl Thromb Hemost. 2021; 27: 10760296211003983.

[20]

Gando S, Wada T. Thromboplasminflammation in COVID-19 coagulopathy: three viewpoints for diagnostic and therapeutic strategies. Front Immunol. 2021; 12: 649122.

[21]

Cezar-Junior AB, Faquini IV, Silva JLJ, de Carvalho Junior EV, Lemos LEAS, Freire Filho JBM, et al. Subarachnoid hemorrhage and COVID-19: association or coincidence? Medicine (Baltimore). 2020; 99: e23862.

[22]

Ursell MR, Marras CL, Farb R, Rowed DW, Black SE, Perry JR. Recurrent intracranial hemorrhage due to postpartum cerebral angiopathy: implications for management. Stroke. 1998; 29: 1995-8.

[23]

Poyiadji N, Shahin G, Noujaim D, Stone M, Patel S, Griffith B. COVID-19-associated acute hemorrhagic necrotizing encephalopathy: imaging features. Radiology. 2020; 296: E119-20.

[24]

Yeo SJ, Kim SJ, Kim JH, Lee HJ, Kook YH. Influenza A virus infection modulates the expression of type IV collagenase in epithelial cells. Arch Virol. 1999; 144: 1361-70.

[25]

Dowlati E, Mualem W, Carpenter A, Chang JJ, Felbaum DR, Sur S, et al. Early fevers and elevated neutrophil-to-lymphocyte ratio are associated with repeat endovascular interventions for cerebral vasospasm in patients with aneurysmal subarachnoid hemorrhage. neurocrit care. 2021;[Epub ahead of print].

[26]

Barpujari A, Patel C, Zelmonovich R, Clark A, Patel D, Pierre K, et al. Pharmaceutical management for subarachnoid hemorrhage. Recent Trends Pharm Sci Res. 2021; 3: 16-30.

[27]

Ascanio LC, Gupta R, Tachie-Baffour Y, Chida K, Dmytriw AA, Enriquez-Marulanda A, et al. Effect of cerebrospinal fluid drainage on clinical outcomes following aneurysmal subarachnoid hemorrhage. J Clin Neurosci. 2022; 97: 1-6.

[28]

Wintermark M, Ko NU, Smith WS, Liu S, Higashida RT, Dillon WP. Vasospasm after subarachnoid hemorrhage: utility of perfusion CT and CT angiography on diagnosis and management. AJNR Am J Neuroradiol. 2006; 27: 26-34.

[29]

Gessler F, Mutlak H, Lamb S, Hartwich M, Adelmann M, Platz J, et al. The impact of tracheostomy timing on clinical outcome and adverse events in poor-grade subarachnoid hemorrhage. Crit Care Med. 2015; 43: 2429-38.

[30]

Bassi TG, Rohrs EC, Fernandez KC, Ornowska M, Nicholas M, Gani M, et al. Brain injury after 50 h of lung-protective mechanical ventilation in a preclinical model. Sci Rep. 2021; 11: 5105.

[31]

Bilotta F, Giordano G, Sergi PG, Pugliese F. Harmful effects of mechanical ventilation on neurocognitive functions. Crit Care. 2019; 23: 273.

[32]

Maslove DM, Sibley S, Boyd JG, Goligher EC, Munshi L, Bogoch II, et al. Complications of critical COVID-19: diagnostic and therapeutic considerations for the mechanically ventilated patient. Chest. 2021;[Epub ahead of print].

[33]

Cusack R, Garduno A, Elkholy K, Martíƴn-Loeches I. Novel investigational treatments for ventilator-associated pneumonia and critically ill patients in the intensive care unit. Expert Opin Investig Drugs. 2022; 31: 173-92.

[34]

Coelembier C, Venet F, Demaret J, Viel S, Lehot JJ, Dailler F, et al. Impact of ventilator-associated pneumonia on cerebrospinal fluid inflammation during immunosuppression after subarachnoid hemorrhage: a pilot study. J Neurosurg Anesthesiol. 2022; 34: e57-62.

[35]

Karic T, Røe C, Nordenmark TH, Becker F, Sorteberg W, Sorteberg A. Effect of early mobilization and rehabilitation on complications in aneurysmal subarachnoid hemorrhage. J Neurosurg. 2017; 126: 518-26.

[36]

Shah SO, Kraft J, Ankam N, Bu P, Stout K, Melnyk S, et al. Early ambulation in patients with external ventricular drains: results of a quality improvement project. J Intensive Care Med. 2018; 33: 370-4.

[37]

Scheer M, Harder A, Wagner S, Ibe R, Prell J, Scheller C, et al. Case report of a fulminant non-aneurysmal convexity subarachnoid hemorrhage after COVID-19. Interdiscip Neurosurg. 2022; 27: 101437.

[38]

Mazeraud A, Robba C, Rebora P, Iaquaniello C, Vargiolu A, Rass V, et al. Acute distress respiratory syndrome after subarachnoid hemorrhage: incidence and impact on the outcome in a large multicenter, retrospective cohort. Neurocrit Care. 2021; 34: 1000-8.

[39]

Moreno G, Carbonell R, Martin-Loeches I, Solé-Violán J, Correig I Fraga E, Gómez J, et al; COVID-19 SEMICYUC Working Group. Corticosteroid treatment and mortality in mechanically ventilated COVID-19-associated acute respiratory distress syndrome (ARDS) patients: a multicentre cohort study. Ann Intensive Care. 2021; 11: 159.

[40]

Wawrzeniak IC, Regina Rios Vieira S, Almeida Victorino J. Weaning from mechanical ventilation in ARDS: aspects to think about for better understanding, evaluation, and management. Biomed Res Int. 2018; 2018: 5423639.

[41]

AK AK, Anjum F. Ventilator-induced lung injury (VILI) [Updated 2021 Dec 15]. In: StatPearls. Treasure Island (FL): StatPearls Publishing; 2022.

[42]

Pavord S, Scully M, Hunt BJ, Lester W, Bagot C, Craven B, et al. Clinical features of vaccine-induced immune thrombocytopenia and thrombosis. N Engl J Med. 2021; 385: 1680-9.

[43]

Bérezné A, Bougon D, Blanc-Jouvan F, Gendron N, Janssen C, Muller M, et al. Deterioration of vaccine-induced immune thrombotic thrombocytopenia treated by heparin and platelet transfusion: insight from functional cytometry and serotonin release assay. Res Pract Thromb Haemost. 2021; 5: e12572.

[44]

Cleaver J, Ibitoye R, Morrison H, Flood R, Crewdson K, Marsh A, et al. Endovascular treatment for vaccine-induced cerebral venous sinus thrombosis and thrombocytopenia following ChAdOx1 nCoV-19 vaccination: a report of three cases. J Neurointerv Surg. 2021;[Epub ahead of print].

[45]

Waraich A, Williams G. Haematuria, a widespread petechial rash, and headaches following the Oxford AstraZeneca ChAdOx1 nCoV-19 Vaccination. BMJ Case Rep. 2021; 14: e245440.

[46]

Nevzorova TA, Mordakhanova ER, Daminova AG, Ponomareva AA, Andrianova IA, Le Minh G, et al. Platelet factor 4-containing immune complexes induce platelet activation followed by calpain-dependent platelet death. Cell Death Discov. 2019; 5: 106.

[47]

McGonagle D, De Marco G, Bridgewood C. Mechanisms of immunothrombosis in vaccine-induced thrombotic thrombocytopenia (VITT) compared to natural SARS-CoV-2 infection. J Autoimmun. 2021; 121: 102662.

[48]

Goldman M, Hermans C. Thrombotic thrombocytopenia associated with COVID-19 infection or vaccination: possible paths to platelet factor 4 autoimmunity. PLoS Med. 2021; 18: e1003648.

[49]

Pang X, Liu H, He X, Ji T, Zhu Y, Cui Y. Potential anionic substances binding to platelet factor 4 in vaccine-induced thrombotic thrombocytopenia of ChAdOx1-S vaccine for SARS-CoV-2. Front Immunol. 2022; 12: 782335.

PDF (1534KB)

0

Accesses

0

Citation

Detail

Sections
Recommended

/

〈 〉